JPY1,404.00
1.37% yesterday
Tokyo, Jun 27, 08:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Stock price

JPY1,402.00
-2.50 0.18% 1M
-142.50 9.23% 6M
-132.50 8.63% YTD
-197.00 12.32% 1Y
-761.00 35.18% 3Y
-411.50 22.69% 5Y
-341.00 19.56% 10Y
+660.00 88.95% 20Y
Tokyo, Closing price Fri, Jun 27 2025
+17.00 1.23%
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key metrics

Basic
Market capitalization
JPY2.5t
Enterprise Value
JPY3.1t
Net debt
JPY613.1b
Cash
JPY218.3b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
49.47 | 15.15
P/S
1.30 | 1.27
EV/Sales
1.62 | 1.58
EV/FCF
22.65
P/B
1.66
Dividends
DPS
JPY78.00
Yield 1Y | 5Y
5.56% | 3.64%
Growth 1Y | 5Y
5.41% | 13.18%
Payout 1Y | 3Y
261.12% | 221.98%
Increased
14 Years
Financials (TTM | estimate)
Revenue
JPY1.9t | JPY2.0t
EBITDA
JPY177.0b | JPY433.0b
EBIT
JPY40.2b
Net Income
JPY50.7b | JPY165.7b
Free Cash Flow
JPY137.2b
Growth (TTM | estimate)
Revenue
-3.35% | 3.02%
EBITDA
-27.17% | 144.65%
EBIT
-70.22%
Net Income
1.14% | 226.57%
Free Cash Flow
52.46%
Margin (TTM | estimate)
Gross
81.74%
EBITDA
9.26% | 21.98%
EBIT
2.10%
Net
2.65% | 8.41%
Free Cash Flow
7.17%
Financial Health
Equity Ratio
45.31%
Return on Equity
3.35%
ROCE
1.77%
ROIC
2.81%
Debt/Equity
0.55
More
EPS
JPY28.34
FCF per Share
JPY76.62
Short interest
-
Employees
14.75k
Rev per Employee
JPY129.61m
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Astellas Pharma forecast:

11x Buy
55%
8x Hold
40%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Astellas Pharma forecast:

Buy
55%
Hold
40%
Sell
5%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,912,323 1,912,323
3% 3%
100%
- Direct Costs 349,206 349,206
3% 3%
18%
1,563,117 1,563,117
3% 3%
82%
- Selling and Administrative Expenses 843,032 843,032
10% 10%
44%
- Research and Development Expense 327,651 327,651
9% 9%
17%
177,011 177,011
27% 27%
9%
- Depreciation and Amortization 136,762 136,762
27% 27%
7%
EBIT (Operating Income) EBIT 40,249 40,249
70% 70%
2%
Net Profit 50,747 50,747
1% 1%
3%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today